Previous 10 | Next 10 |
VANCOUVER, British Columbia, April 29, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD” ) a clinical stage pharmaceutical company is pleased to announce that through its license partner, Moleculin Biotech, Inc...
HOUSTON , April 28, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it is now authorized by the Polish Department of Registration of Me...
VANCOUVER, British Columbia, April 23, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD” ) a clinical stage pharmaceutical company is pleased to provide an update on its Annamycin drug candidate. Through its li...
HOUSTON , April 22, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it has welcomed Dr. Richard Whitley to its Science Advisory Board to g...
VANCOUVER, British Columbia, April 21, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company along with its development partner CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (ȁ...
Moleculin Biotech (NASDAQ: MBRX ) has entered into an agreement with ImQuest Biosciences to expand in vitro and in vivo testing of WP1122 for the treatment of COVID-19. More news on: Moleculin Biotech, Inc., Healthcare stocks news, Read more ...
HOUSTON , April 20, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it has entered into an agreement with ImQuest Biosciences to expand...
Gainers: Taronis Technologies (NASDAQ: TRNX ) +87% . More news on: Taronis Technologies, Inc., Golden Bull Limited, Genetic Technologies Limited, Stocks on the move, , Read more ...
Pulmatrix (NASDAQ: PULM ) -27% on $8M direct offering . More news on: Pulmatrix, Inc., Moleculin Biotech, Inc., Cutera, Inc., Stocks on the move, , Read more ...
Edison Nation (NASDAQ: EDNT ) +169% on over $10M order . More news on: Edison Nation, Inc., Soligenix, Inc., Atossa Therapeutics, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML PR Newswire HOUSTON , July 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfoli...
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial PR Newswire – 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations – Current median durability of response (mDOR) of CRc's = 6 months and in...